SEC 13F Intelligence

Orbimed Advisors LLC / SPRY

Orbimed Advisors LLC’s Ars Pharmaceuticals Inc Position

Does Orbimed Advisors LLC own Ars Pharmaceuticals Inc (SPRY)? Yes — 8.29M shares worth $67M (+1.32% of its 13F portfolio) as of Q1 2026.

Position Value
$67M
Q1 2026
Shares
8.29M
% of Portfolio
+1.32%
Quarters Held
22
currently held

Position History SPRY

Reported value by quarter
Q4 ’20: $405MQ4 ’20Q1 ’21: $381MQ2 ’21: $270MQ3 ’21: $87MQ3 ’21Q4 ’21: $58MQ1 ’22: $31MQ2 ’22: $37MQ2 ’22Q3 ’22: $46MQ4 ’22: $75MQ1 ’23: $57MQ1 ’23Q2 ’23: $59MQ3 ’23: $35MQ4 ’23: $51MQ4 ’23Q1 ’24: $94MQ2 ’24: $79MQ3 ’24: $120MQ3 ’24Q4 ’24: $87MQ1 ’25: $104MQ2 ’25: $145MQ2 ’25Q3 ’25: $83MQ4 ’25: $97MQ1 ’26: $67MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20268.29M$67M+1.32%
Q4 20258.29M$97M+1.97%
Q3 20258.29M$83M+1.96%
Q2 20258.29M$145M+3.61%
Q1 20258.29M$104M+2.49%
Q4 20248.29M$87M+1.80%
Q3 20248.29M$120M+2.18%
Q2 20249.24M$79M+1.55%
Q1 20249.24M$94M+1.73%
Q4 20239.24M$51M+1.01%
Q3 20239.24M$35M+0.74%
Q2 20238.74M$59M+1.06%
Q1 20238.74M$57M+1.12%
Q4 20228.74M$75M+1.43%
Q3 20228.74M$46M+0.86%
Q2 20228.74M$37M+0.67%
Q1 20228.74M$31M+0.50%
Q4 20218.74M$58M+0.75%
Q3 20218.74M$87M+0.96%
Q2 20218.74M$270M+2.73%
Q1 20218.74M$381M+3.57%
Q4 20208.74M$405M+3.54%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Orbimed Advisors LLC’s full portfolio or all institutional holders of SPRY.